Molly Henderson Sells 1,291 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHATGet Free Report) CFO Molly Henderson sold 1,291 shares of the stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $8.00, for a total value of $10,328.00. Following the transaction, the chief financial officer now directly owns 98,156 shares in the company, valued at approximately $785,248. This represents a 1.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Phathom Pharmaceuticals Price Performance

Phathom Pharmaceuticals stock opened at $7.45 on Friday. The company has a market cap of $509.41 million, a price-to-earnings ratio of -1.31 and a beta of 0.56. Phathom Pharmaceuticals, Inc. has a 12 month low of $6.07 and a 12 month high of $19.71. The stock’s 50-day moving average is $12.11 and its 200-day moving average is $13.09.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PHAT. Bank of New York Mellon Corp increased its position in shares of Phathom Pharmaceuticals by 20.5% in the second quarter. Bank of New York Mellon Corp now owns 114,721 shares of the company’s stock worth $1,182,000 after acquiring an additional 19,500 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Phathom Pharmaceuticals by 42.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company’s stock valued at $104,000 after purchasing an additional 2,987 shares in the last quarter. Rhumbline Advisers raised its position in Phathom Pharmaceuticals by 17.1% in the second quarter. Rhumbline Advisers now owns 55,178 shares of the company’s stock valued at $568,000 after purchasing an additional 8,075 shares during the period. Marshall Wace LLP acquired a new position in shares of Phathom Pharmaceuticals during the second quarter worth about $1,161,000. Finally, Oracle Investment Management Inc. purchased a new stake in shares of Phathom Pharmaceuticals in the second quarter worth about $2,318,000. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PHAT. HC Wainwright reiterated a “buy” rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Wednesday, December 11th.

View Our Latest Report on Phathom Pharmaceuticals

About Phathom Pharmaceuticals

(Get Free Report)

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

Further Reading

Insider Buying and Selling by Quarter for Phathom Pharmaceuticals (NASDAQ:PHAT)

Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.